Back to Search
Start Over
Recognizing mucormycosis in an immunocompromised patient.
- Source :
-
JAAPA : official journal of the American Academy of Physician Assistants [JAAPA] 2020 Dec; Vol. 33 (12), pp. 23-25. - Publication Year :
- 2020
-
Abstract
- Mucormycosis is an aggressive, angioinvasive fungal infection with a predilection for the rhino-orbital cavity, predominantly in immunocompromised patients such as patients with uncontrolled diabetes. Prognosis is very poor, with a survival rate of 40% to 50%; therefore, early detection and initiation of treatment is paramount. Presenting symptoms are vague and mucormycosis is rare, so recognition, awareness, and knowledge of this infection are key to timely intervention and enhanced patient survival.
- Subjects :
- Adult
Amphotericin B administration & dosage
Antifungal Agents administration & dosage
Debridement
Dexamethasone administration & dosage
Dexamethasone adverse effects
Diagnosis, Differential
Fluconazole administration & dosage
Fluconazole adverse effects
Humans
Immunosuppressive Agents administration & dosage
Immunosuppressive Agents adverse effects
Interleukin 1 Receptor Antagonist Protein administration & dosage
Interleukin 1 Receptor Antagonist Protein adverse effects
Lymphohistiocytosis, Hemophagocytic drug therapy
Male
Prognosis
Sinusitis diagnosis
Sinusitis etiology
Sinusitis therapy
Therapeutic Irrigation methods
Tomography, X-Ray Computed
Immunocompromised Host
Mucormycosis
Paranasal Sinuses
Sinusitis microbiology
Subjects
Details
- Language :
- English
- ISSN :
- 1547-1896
- Volume :
- 33
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- JAAPA : official journal of the American Academy of Physician Assistants
- Publication Type :
- Academic Journal
- Accession number :
- 33234891
- Full Text :
- https://doi.org/10.1097/01.JAA.0000721656.13462.67